🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise worldwide, with estimates suggesting over 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

According to data detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The study enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.